Trump’s pharma tariffs put Singapore at ‘greatest risk’ among major exporters if no exemptions granted: economists
Without exemptions, the effective tariff rate on the Republic’s shipments could exceed 30%, compared with 4% now
Add BT as a preferred source
[SINGAPORE] The Trump administration’s latest tariff salvo – this time aimed at branded or patented pharmaceutical goods – could hit Singapore particularly hard, economists warned.
On Thursday (Sep 25), Trump announced a 100 per cent tariff on imports of branded or patented pharmaceutical goods from Oct 1, unless a company has already begun construction of a plant in the United States.
Pharmaceutical firms that have broken ground on US facilities will receive exemptions, Trump said.
TRENDING NOW
On the board but frozen out: The Taib family feud tearing Sarawak construction giant apart
Thai and Vietnamese farmers may stop planting rice because of the Iran war. Here’s why
MAS convenes bank CEOs over AI cyberthreats; boards told to own risks, not leave to IT teams
Is it time to scrap COE categories for cars?
